Akebia Therapeutics Q2 Sales $62.472M Beat $47.637M Estimate

Akebia Therapeutics (NASDAQ: AKBA) reported quarterly sales of $62.472 million which beat the analyst consensus estimate of $47.637 million by 31.14 percent. This is a 43.13 percent increase over sales of $43.648 million the same period last year.